BrainsWay Deep TMS

12/22/2025

Expanding access for adolescent mental health care.

We’re pleased to share that Optum Behavioral Health has expanded its medical policy to include coverage for Deep TMS™ therapy for adolescents aged 15 and older with confirmed major depressive disorder (MDD) — now adding over 48 million covered lives to the growing list of payers supporting this important option.

Deep TMS is FDA-cleared as an adjunct therapy for adolescents with MDD, building on its established role in adult care and supported by robust clinical evidence.

This coverage expansion reflects continued progress in broadening access to non-drug treatment options for young people facing depression.

https://ow.ly/WzaN50XNe2k

11/24/2025

The FDA has granted 510(k) clearance for TMS as an adjunctive treatment for Major Depressive Disorder in young people ages 15–21.

Real-world data from more than 1,100 patients across 35 centers showed strong safety and meaningful improvement in depression symptoms.

This clearance expands access to a much-needed, noninvasive treatment option for younger patients and supports continued innovation in neuromodulation.

👉 Read the full Healio article here:
https://www.healio.com/news/psychiatry/20251119/fda-grants-510k-clearance-for-tms-as-adjunctive-for-major-depressive-disorder-in-young-people

11/21/2025

Deep TMS™ becomes first and only TMS device cleared in treatment of patients ages 15 to 86 suffering from depression

Learm more: https://ow.ly/vJE250XvLx2

11/10/2025

We’re excited to be attending the Behavioral Health Tech Conference in San Diego, November 11–13!

Join us as we connect with leaders advancing mental health innovation and explore how Deep TMS® technology is shaping the future of behavioral health care.

If you would like to arrange a meeting with the BrainsWay team, please email deeptms@brainsway.com.

10/31/2025

Happy Halloween! 👻🎃

10/27/2025

BrainsWay at DGPPN 2025 Berlin

We’re excited to join the DGPPN Congress 2025 in Berlin, one of the world’s leading events in psychiatry, psychotherapy, psychosomatics, and neuroscience.

📍 Find us at Booth #60
📅 November 26–29, 2025
🏛 CityCube Berlin – Messedamm 26, 14055 Berlin, Germany

Join us to explore how BrainsWay’s Deep TMS™ technology is transforming mental health treatment worldwide, with FDA-cleared and clinically proven solutions for Depression, OCD, and Smoking Addiction.

Let’s connect in Berlin to discuss innovation, share insights, and shape the future of mental health together.

10/10/2025

🌍 Today is World Mental Health Day.

Mental health is an essential part of overall well-being, and everyone deserves access to care and support. At BrainsWay, we are dedicated to expanding treatment options and helping more people find hope and healing. 💙💚

Let’s keep the conversation open, reduce stigma, and support each other.

10/06/2025

It's OCD Awareness Month! Did you know there are 5 effective strategies for treating OCD?

In addition to medication, therapy and lifestyle changes, people with OCD may also benefit from ™.

10/02/2025

Expanding Access to Breakthrough Mental Health Care in Chester County

We’re excited to welcome MooreWays to Mental Health in Exton’s Eagleview community as the newest member of the BrainsWay network. By offering Deep TMS™, MooreWays is helping bring cutting-edge, non-invasive mental health care to more people across the region.

We’re proud to see Deep TMS reaching more communities and transforming more lives, one clinic and one patient at a time.

https://vista.today/2025/09/mooreways-deep-transcranial-magnetic-stimulation/

09/30/2025

🌎 BrainsWay at AAP 2025

Last week, BrainsWay had the pleasure of participating in the Argentinian Association for Psychiatry (AAP) annual meeting in Buenos Aires.

Our team connected with leaders in the field like Dr. Leandro Piedimonte to discuss how Deep TMS™ is expanding treatment possibilities for patients with depression, OCD, and other mental health conditions.

It was inspiring to see the enthusiasm around neuromodulation and the continued growth of innovative mental health solutions across Latin America. We’re excited to build on these conversations and support clinicians in delivering life-changing care around the world. 💡🧠

09/29/2025

🚨 Featured in MassDevice 🚨

BrainsWay has received expanded FDA clearance for our Deep TMS™ system, now including an accelerated treatment protocol for Major Depressive Disorder (MDD) and patients with comorbid anxiety symptoms.

🔹 6 treatment days vs. 4 weeks under the standard protocol
🔹 Each session lasts less than 10 minutes
🔹 Supported by a multicenter, randomized, controlled study
🔹 Comparable efficacy with fewer clinic visits

👉 Read the full MassDevice feature: https://www.brainsway.com/?post_type=news_events&p=14746&preview=true

09/25/2025

A Promising Approach for Tough-to-Treat Depression

For patients who haven’t responded to standard treatments, combining ketamine with Deep Transcranial Magnetic Stimulation (Deep TMS™) may offer new hope.

As Dr. Colleen Hanlon, BrainsWay’s VP of Global Medical Affairs, explained to Healio:

⚡ Ketamine can bring rapid relief, especially for acute symptoms.
🧠 Deep TMS™ builds lasting changes over time, with high response and remission rates that can last months.

Used in sequence — often starting with ketamine and followed by Deep TMS™ — the two treatments may work together to improve outcomes for patients with refractory depression.

Read more about this coordinated approach and Dr. Hanlon’s insights.

https://www.healio.com/news/psychiatry/20250923/coordinated-transcranial-magnetic-stimulation-ketamine-may-benefit-refractory-depression

Transcranial magnetic stimulation and ketamine have been effective in treating depression. But when patients still struggle after using them individually, coordinated treatment offers promise, Colleen A. Hanlon, PhD, told Healio. “You can think of the brain as an organ that’s both chemic...